Bio­Marin puts Lon Car­don in charge of port­fo­lio strat­e­gy while gene ther­a­py fil­ings get un­der­way

As Bio­Marin shoots for the first-ever ap­proval of a he­mo­phil­ia gene ther­a­py — and the multi­bil­lion-dol­lar rev­enue ex­pect­ed to fol­low — the com­pa­ny is pro­mot­ing CSO Lon Car­don to a po­si­tion where he can help sketch the next ren­di­tion of its rare dis­ease port­fo­lio.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER